סטיוורגה Israeli - Kiebrania - Ministry of Health

סטיוורגה

bayer israel ltd - regorafenib - טבליות מצופות פילם - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and if kras wild-type, an anti-egfr therapy.for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate

פמפירה 10 מג Israeli - Kiebrania - Ministry of Health

פמפירה 10 מג

medison pharma ltd - fampridine - טבליות בשחרור ממושך - fampridine 10 mg - fampridine - fampridine - fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7)

אבילק סירופ Israeli - Kiebrania - Ministry of Health

אבילק סירופ

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

טייבסו Israeli - Kiebrania - Ministry of Health

טייבסו

rafa laboratories ltd - treprostinil as sodium salt - תמיסה לשאיפה - treprostinil as sodium salt 1.74 mg / 2.9 ml - treprostinil - treprostinil - treatment of pulmonary arterial hypertension in patients with nyha class iii symptoms, to increase walk distance.

טרנדייט טבליות 100 מג Israeli - Kiebrania - Ministry of Health

טרנדייט טבליות 100 מג

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

אפלומיצין Israeli - Kiebrania - Ministry of Health

אפלומיצין

padagis israel pharmaceuticals ltd, israel - gentamicin sulfate; prednisolone - קרם - prednisolone 0.5 %; gentamicin sulfate 0.16 % - prednisolone and antibiotics - prednisolone and antibiotics - for the treatment of skin inflammation associated with bacterial infection.

פלאג'יל 250 מג טבליות Israeli - Kiebrania - Ministry of Health

פלאג'יל 250 מג טבליות

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

גאמאגארד S/D אימונוגלובולין תוך ורידי 2.5 גר' Israeli - Kiebrania - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 2.5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 5 גר' Israeli - Kiebrania - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 10 גר' Israeli - Kiebrania - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 10 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation